At the largest hospital in Brooklyn, doctors are working to address disparities for patients facing advanced heart failure.

Nat Clin Pract Cardiovasc Med. 2006;3(7):346-347. Since the first widespread clinical application of left ventricular assist devices (LVADs) for patients with end-stage heart failure in the ...

AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...

The company’s RECOVER-AV trial is intended to further the adoption of its AlphaVac F1885 system in the European market.

Multi-channel models enhance cardiotoxicity testing, offering more accurate and human-relevant insights for safer drug ...

Boston Scientific (NYSE: BSX) received FDA approval to expand the indication for its current-generation Ingevity+ pacing ...

A Vascular Access Device (VAD) is a medical device designed to provide access to a patient’s bloodstream for various medical treatments, procedures, and interventions. It allows healthcare ...

AngioDynamics, Inc. announced the launch of the RECOVER AV trial of the company’s AlphaVac F18⁸⁵ multipurpose mecha ...

CVKD READ THE FULL CVKD RESEARCH REPORT We are initiating coverage of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) with a $30.00 valuation. Cadrenal is a biopharmaceutical developing innovative therapies ...

NIDCM is characterized by left-ventricular or biventricular dilatation and contractile ... people with NIDCM each year based largely on LVEF criteria. However, most device recipients don't end up with ...

This year, the SOFMEDICA Group celebrates three decades of innovation in the healthcare industry. Founded in 1994, the Group ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...